Emraclidine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SchizophreniaDementia

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

1

Celexa

AbbVie

Preclinical

42

Resotran

Takeda

Preclinical

13

Inapsine

Alnylam Pharmaceuticals

Preclinical

14

Ozempic

Novo Nordisk

Preclinical

15

Zocor

OOrganon and Co

Preclinical

66

Depakote

AbbVie

Preclinical

—7

Ibrance

Pfizer

Preclinical

—8

Emraclidine

AbbVie

Phase 2

39

Lunesta

Akero Therapeutics

Preclinical

310

Persantine

Boehringer Ingelheim

Preclinical

1Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Schizophrenia3 trials

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Completed·AbbVie·Phase 2·NCT05227690·385 enrolled

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Completed·AbbVie·Phase 2·NCT05227703·391 enrolled

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

Recruiting·AbbVie·Phase 2·NCT07145918·268 enrolled

Adult2 trials

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

Completed·CCerevel Therapeutics, LLC·Phase 1·NCT05915546·16 enrolled

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Completed·CCerevel Therapeutics, LLC·Phase 1·NCT06366243·20 enrolled

Renal Impairment1 trial

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Completed·AbbVie·Phase 1·NCT05940402·58 enrolled

Adverse Events1 trial

A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants

Recruiting·AbbVie·Phase 1·NCT07219030·32 enrolled

Hepatic Impairment1 trial

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Completed·AbbVie·Phase 1·NCT05935033·38 enrolled

4 more indications

Dementia1 trial

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

Completed·AbbVie·Phase 1·NCT05644977·17 enrolled

Metformin1 trial

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Completed·CCerevel Therapeutics, LLC·Phase 1·NCT05965219·60 enrolled

Metabolism1 trial

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

Completed·CCerevel Therapeutics, LLC·Phase 1·NCT06301971·8 enrolled

Unspecified1 trial

A Phase 1, Open-label, Single Dose, Crossover Study to Assess the Relative Bioavailability of Emraclidine Formulations in Healthy Adult Subjects

Active, not recruiting·AbbVie·Phase 1·NCT07587008·12 enrolled

Details

Drug Info

Related News